Infinity Pharmaceuticals Inc. (NASDAQ: INFI) stock declined by 2.52% at the last close whereas the INFI stock price declined by 0.43% today. Infinity Pharmaceuticals is a medical biotechnology business working on eganelisib (IPI-549) which is an oral immuno-oncology macrophage reprogramming therapy that has been shown to target a core biologic mechanism of immune suppression in cancer in several clinical trials.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
INFI stock’ Update
In the San Antonio Breast Cancer Symposium (SABCS 2021), the company will host an investor event on new data from the current MARIO-3 clinical study at 9:30 a.m. ET today.
Hatem Soliman, MD, MARIO-3 Investigator, and Medical Director, Clinical Trials Office at the Moffitt Cancer Center, will provide a presentation during the webinar.
Dr. Soliman will speak about the changing therapy landscape for TNBC, as well as the substantial unfulfilled need for individuals with frontline, metastatic TNBC. Dr. Soliman will examine the MARIO-3 trial design and outline patient data and baseline features, as well as the MARIO-3 study’s revised safety and efficacy findings. Dr. Robert Ilaria, Infinity’s Chief Medical Officer, will discuss eganelisib’s mode of action and translational findings from the MARIO-3 research.
Furthermore,
Hatem Soliman is one of the top doctors for breast cancer in the country also he is the researcher on the MARIO-3 trial. Dr. Soliman is the Medical Director of the Moffitt Cancer Center’s Clinical Trials Office. Since joining the faculty at Moffitt in 2008, he has vast expertise as a clinical investigator undertaking both translational research in breast cancer immunotherapy and leading multiple clinical trials as a primary investigator.
This current development could be the reason behind the surge in INFI stock price during pre-market. The stockholders must be looking forward to the new findings obtained MARIO-3 clinical study which will be presented today.
